Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

8.6K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
8.6K
T Cell Types and Functions01:24

T Cell Types and Functions

2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Cancer discovery·2026
Same author

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

The Journal of experimental medicine·2026
Same author

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Immune checkpoint blockade augments lymphodepleting chemotherapy-induced antitumor immunity by expanding effector CD8+ T cell clones.

Cancer research·2026
Same author

Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival.

Cancer discovery·2026
Same author

Reprogramming of TLR-Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer.

Cancer research·2026
Same journal

Multinucleated giant cells in human pancreatic cancer are a distinct macrophage population undergoing a DNA damage response and associated with an aggressive tumor microenvironment.

Cancer immunology research·2026
Same journal

Fueling Immunotherapy Resistance: SSBP4 Links Tumor Cholesterol Biosynthesis to Immune Evasion.

Cancer immunology research·2026
Same journal

Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

Cancer immunology research·2026
Same journal

Cancer intrinsic protein neddylation modulates the intra-tumoral immune landscape to constrain immune checkpoint blockade therapy.

Cancer immunology research·2026
Same journal

ADAR1 deficiency in pancreatic cancer cells potentiates cDC1 activation and promotes sensitization to immunotherapy.

Cancer immunology research·2026
Same journal

DNA hypomethylating agents preserve T cell stemness and potentiate the efficacy of CD3-bispecific antibodies.

Cancer immunology research·2026
See all related articles

Related Experiment Video

Updated: Jan 13, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.4K

IL10R Inhibition Induces Neutrophil Tumoricidal Activity.

Danny N Khalil1,2, Ricardo Gomez2, Amit Regev2,3

  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Cancer Immunology Research
|January 7, 2026
PubMed
Summary
This summary is machine-generated.

Neutrophils can directly kill tumor cells via degranulation, independent of T cells. This pathway, enhanced by anti-CD40 therapy and G-CSF, shows promise for cancer treatment.

More Related Videos

Isolation and Characterization of Neutrophils with Anti-Tumor Properties
10:15

Isolation and Characterization of Neutrophils with Anti-Tumor Properties

Published on: June 19, 2015

25.4K
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.3K

Related Experiment Videos

Last Updated: Jan 13, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.4K
Isolation and Characterization of Neutrophils with Anti-Tumor Properties
10:15

Isolation and Characterization of Neutrophils with Anti-Tumor Properties

Published on: June 19, 2015

25.4K
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.3K

Area of Science:

  • Immunology
  • Cancer Biology
  • Oncology

Background:

  • Neutrophil roles in antitumor immunity are known, but direct tumor cell killing is less understood.
  • Investigating neutrophils' direct cytotoxic effects on tumor cells is crucial for novel cancer therapies.

Purpose of the Study:

  • To determine if neutrophils can directly kill tumor cells independently of T cell responses.
  • To elucidate the mechanisms and therapeutic potential of neutrophil-mediated tumor cell killing.

Main Methods:

  • Microscopy, single-cell assays, and functional assays were used to observe neutrophil-tumor cell interactions.
  • Preclinical models and Phase 1/1b/2 clinical trials involving anti-CD40 therapy were employed.
  • Analysis of cytokine levels (IL-12, IFNγ, IL-10) and neutrophil expansion (G-CSF) in patients.

Main Results:

  • Anti-CD40 therapy combined with IL-10 receptor blockade induced IL-12 and IFNγ secretion, leading to oncolytic neutrophil activity.
  • Neutrophil-mediated tumor cell killing requires physical contact and degranulation, characterized by an invasive phenotype.
  • Clinical trials showed increased IL-12, IFNγ, and IL-10 post-anti-CD40 therapy; lower IL-10 correlated with better survival.
  • G-CSF-induced neutrophil expansion improved survival in anti-CD40-treated patients.

Conclusions:

  • Neutrophils possess direct oncolytic capabilities, activated through specific therapeutic pathways.
  • This neutrophil-mediated killing mechanism is a potential therapeutic target for advanced cancers.
  • Combining anti-CD40 therapy with G-CSF may enhance survival outcomes in cancer patients.